It’s only fair to share… Valemetostat tosilate バレメトスタットトシル酸塩 Formula C26H34ClN3O4. C7H8O3S CAS 1809336-93-3 Mol weight 660.2205 PMDA JAPAN approved 2022/9/26, Ezharmia 1,3-Benzodioxole-5-carboxamide, 7-chloro-N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl-, (2R)-, compd. with 4-methylbenzenesulfonate (1:1) Antineoplastic, histone methyltransferase inhibitor 1809336-39-7 (free base). 1809336-93-3 (tosylate) 1809336-92-2 (mesylate) 1809336-94-4 (fumarate) 1809336-95-5 (tarate) Synonym: Valemetostat; DS-3201; DS 3201; DS3201; DS-3201b (2R)-7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide mono(4-methylbenzenesulfonate) C26H34ClN3O4▪C7H8O3S : 660.22 …
Gadopiclenol
It’s only fair to share… Gadopiclenol ガドピクレノール; Formula C35H54N7O15. Gd CAS 933983-75-6 Mol weight 970.0912 FDA APPROVED 2022/9/21, Elucirem Diagnostic agent (MR imaging), WHO 10744, P 03277, UNII: S276568KOY EluciremTM; G03277; P03277; VUEWAY (alpha3,alpha6,alpha9-Tris(3-((2,3-dihydroxypropyl)amino)-3-oxopropyl)-3,6,9,15-tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)-kappaN3,kappaN6,kappaN9,kappaN15,kappaO3,kappaO6,kappaO9)gadolinium OriginatorGuerbet ClassDiagnostic agents; Gadolinium-containing contrast agents; Macrocyclic compounds; Propylamines; Pyridines Mechanism of ActionMagnetic resonance imaging enhancers RegisteredCNS disorders Phase IIIUnspecified Phase IILiver cancer 21 Sep …
Eflapegrastim
It’s only fair to share… Eflapegrastim エフラペグラスチム; Molecular Formula C15-H28-N2-O6(C2-H4-O)n Molecular Weight 376.4468 Formula C3070H4764N806O927S23.(C2H4O)n UNII: UT99UG9QJX HM10460A SPI-2012 HNK460 Reducing neutropenia and the incidence of infecton in patients with cancer (2S)-1-{3-[2-(3-{[(1S,2R)-1-carboxy-2-hydroxypropyl]amino}propoxy)ethoxy]propyl}pyrrolidine-2-carboxylic acid APPROVED FDA 2022/9/9, Rolvedon CAS: 1384099-30-2 LAPS-GCSF, ROLONTIS Antineutropenic, Leukocyte growth factor Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-, 1-ether with immunoglobulin G4 [1-[1-(3-hydroxypropyl)proline]] (human Fc fragment), (3→3′)–disulfide with immunoglobulin G4 …
Terlipressin acetate
It’s only fair to share… Terlipressin acetate テルリプレシン酢酸塩 C52H74N16O15S2. (C2H4O2)x CAS: 914453-96-6 ACETATEFREE FORM 14636-12-5 Terlipressin acetate (JAN); Heamopressin (TN); Terlivaz (TN) Cardiovascular agent Antidiuretic, Vasoconstrictor, Arginine vasopressin receptor agonist USFDA APPROVED 2022/9/14 An inactive peptide prodrug that is slowly converted in the body to lypressin. It is used to control bleeding of ESOPHAGEAL VARICES and …
LORPUCITINIB
It’s only fair to share… LORPUCITINIB JNJ 64251330 2230282-02-5 UNII-OE1QTY7C25 Molecular Weight 408.50 Formula C22H28N6O2 1-(TRANS-4-(CYANOMETHYL)CYCLOHEXYL)-1,6-DIHYDRO-N-(2-HYDROXY-2-METHYLPROPYL)IMIDAZO(4,5-D)PYRROLO(2,3-B)PYRIDINE-2-ACETAMIDE 2-[3-[4-(cyanomethyl)cyclohexyl]-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaen-4-yl]-N-(2-hydroxy-2-methylpropyl)acetamide is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease. Lorpucitinib is an orally bioavailable pan-inhibitor of the Janus associated-kinases (JAKs), with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, lorpucitinib works in the gastrointestinal (GI) tract …
Betibeglogene autotemcel
It’s only fair to share… Betibeglogene autotemcel ベチベグロゲンアウトテムセル 2022/8/17, FDA APPROVED Zynteglo Cellular therapy product Treatment of betathalassemia BB305 LVV, bb 1111 BB305 transduced SCD CD34+ HSCs bb1111 LentiGlobin BB305 LVV-transduced autologous SCD CD34+ HSCs bb1111 LentiGlobin drug product for SCD LentiGlobin drug product for sickle cell disease LentiGlobin for SCD bb1111 Betibeglogene autotemcel, sold under …
ZYIL 1, Usnoflast
It’s only fair to share… ZYIL 1, Usnoflast All new post MARCH 2025 2455519-86-3 [ZYDUS CADILA] ZYIL1 ZYIL-1 ZY-IL1 C21H29N3O3S Ethenesulfonamide, 2-[(2R)-1,2-dimethyl-2-pyrrolidinyl]-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-, (1E)- MW 403.54 (1E)-2-[(2R)-1,2-Dimethyl-2-pyrrolidinyl]-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]ethenesulfonamide PATENTS European Journal of Pharmacology (2023), 957, 175931 WO2020148619 CADILA WO2023026222 ZYDUS WO2023281455 ZYDUS US-2022169605 EP-3911631-A1 JP-2022517113-A SCHEME https://patents.google.com/patent/WO2020148619A1/enhttps://patents.google.com/patent/WO2020148619A1/en WO2020148619 Intermediate-9: Preparation of l-(diphenylphosphoryl)-N-((l,2,3,5,6,7- hexahydro-s-indacen-4-yl)carbamoyl)methanesulfonamide (diphenylphosphoryl)methanesulfonamide [Intermediate 8] (6.0 …
Spesolimab
It’s only fair to share… (Heavy chain) QVQLVQSGAE VKKPGASVKV SCKASGYSFT SSWIHWVKQA PGQGLEWMGE INPGNVRTNY NENFRNKVTM TVDTSISTAY MELSRLRSDD TAVYYCTVVF YGEPYFPYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPEAAGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK (Light chain) QIVLTQSPGT …
Lenacapavir sodium
It’s only fair to share… Lenacapavir sodium レナカパビルナトリウム Formula C39H31ClF10N7O5S2. Na C39H32ClF10N7O5S2 FREE FORM CAS 2283356-12-5 2189684-44-2 FEE FORM Mol weight 990.2641 968.28 FREE FORM 2022/8/17 EMA APPROVED, SUNLECA N-[(1S)-1-[3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2S,4R)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide Treatment of HIV-1 infection PF-3540074, to GS-CA1, GS-6207, GS-HIV, GS-CA1, GS-CA2 Lenacapavir, sold under the brand name Sunlenca, is a medication used to treat HIV/AIDS.[1] It is taken by mouth or by subcutaneous injection.[1] The most common side …
ICENTICAFTOR
It’s only fair to share… QBW 251, ICENTICAFTOR Molecular FormulaC12H13F6N3O3 Average mass361.240 Da 2-Pyridinecarboxamide, 3-amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)- 3-Amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-2-pyridinecarboxamide 3-Amino-6-méthoxy-N-(3,3,3-trifluoro-2-hydroxy-2-méthylpropyl)-5-(trifluorométhyl)-2-pyridinecarboxamide (S)-3-amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2- methylpropyl)-5-(trifluoromethyl)picolinamide 1334546-77-8 [RN] Icenticaftor (development code QBW251) is a drug candidate for the treatment of chronic obstructive pulmonary disease (COPD)[1][2] and cystic fibrosis.[3][4] The drug is being developed by Novartis.[5] Like ivacaftor (which is marketed as Kalydeco), icenticaftor functions by acting as a stimulator of the protein cystic fibrosis transmembrane conductance regulator (CFTR).[5] …